<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1575">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03086369</url>
  </required_header>
  <id_info>
    <org_study_id>15844</org_study_id>
    <secondary_id>I5B-MC-JGDP</secondary_id>
    <secondary_id>2016-001099-31</secondary_id>
    <nct_id>NCT03086369</nct_id>
  </id_info>
  <brief_title>A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and
      gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 11, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicities (DLTs) Phase 1b</measure>
    <time_frame>Cycle 1 (28 Days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS) Phase 2</measure>
    <time_frame>Baseline to Date of Death from Any Cause (Approximately 9 Months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Minimum Concentration (Cmin) of Olaratumab</measure>
    <time_frame>Baseline through End of Study (Approximately 9 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Phase 1b</measure>
    <time_frame>Baseline to Date of Death from Any Cause (Approximately 9 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline to Disease Progression or Death (Approximately 6 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Disease Progression or Death (Approximately 6 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 5.5 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Worsening of the Brief Pain Inventory Short Form Modified (mBPI-sf) &quot;Worst Pain Score&quot;</measure>
    <time_frame>Baseline through Follow-up (Approximately 9 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Sustained Worsening of Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scale Scores</measure>
    <time_frame>Baseline through Follow-up (Approximately 9 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status on the EuroQol 5-Dimension 5 Level (EQ-5D-5L)</measure>
    <time_frame>Baseline through Follow-up (Approximately 9 Months)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Open Label) Olaratumab, nab-paclitaxel and gemcitabine given intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Cohort Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Open Label) Olaratumab, nab-paclitaxel and gemcitabine given IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Double Blind) Olaratumab, nab-paclitaxel and gemcitabine given IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Nab-paclitaxel + Gemcitabine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(Double Blind) Placebo, nab-paclitaxel and gemcitabine given IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaratumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Dose Escalation)</arm_group_label>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Cohort Expansion)</arm_group_label>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Treatment)</arm_group_label>
    <other_name>LY3012207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Dose Escalation)</arm_group_label>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Cohort Expansion)</arm_group_label>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Treatment)</arm_group_label>
    <arm_group_label>Placebo + Nab-paclitaxel + Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Dose Escalation)</arm_group_label>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Cohort Expansion)</arm_group_label>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Treatment)</arm_group_label>
    <arm_group_label>Placebo + Nab-paclitaxel + Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo + Nab-paclitaxel + Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of adenocarcinoma of the exocrine pancreas that
             is metastatic (Stage IV) and not amenable to resection with curative intent.

          -  If present, clinically significant or symptomatic amounts of ascites should be
             drained prior to Day 1.

          -  No prior line of systemic therapy for metastatic disease.

          -  Prior radiation therapy for treatment of cancer is allowed to &lt;25% of the bone
             marrow.

          -  Phase 2: archival tumor tissue or be willing to provide a pre-treatment biopsy.

          -  Measurable or nonmeasurable but evaluable disease as defined by the Response
             Evaluation Criteria in Solid Tumors (RECIST 1.1).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

          -  Discontinued all previous treatments for cancer â‰¥4 weeks prior.

          -  Adequate organ function.

          -  Life expectancy of at least 3 months.

        Exclusion Criteria:

          -  Serious concomitant systemic disorder.

          -  First line treatment for metastatic pancreatic cancer.

          -  Received prior treatment with FOLFOX or FOLFIRINOX.

          -  Have known central nervous system malignancy or metastasis.

          -  Current hematologic malignancies.

          -  Participated within the last 30 days in a clinical trial.

          -  Women with a positive pregnancy test or lactating.

          -  Have endocrine pancreatic tumors or ampullary cancer.

          -  Currently enrolled in another clinical trial.

          -  History of any other cancer unless in complete remission and off treatment for a
             minimum of 3 years.

          -  Known allergy to nab-paclitaxel or gemcitabine or any ingredient of study drug
             formulations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>TGen Clinical Research Services at Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>480-323-1282</phone>
    </contact>
    <investigator>
      <last_name>Erkut Borazanci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology Hematology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>423-242-2858</phone>
    </contact>
    <investigator>
      <last_name>Mark Womack</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>Johanna Bendell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>801-585-1435</phone>
    </contact>
    <investigator>
      <last_name>Ignacio Garrido Laguna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 22, 2017</lastchanged_date>
  <firstreceived_date>March 13, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
